The clinical value of inflammatory factors in evaluating the prognosis of patients with acute myeloid leukemia

Inflammatory Factors in AML Prognosis

  • Jianghuizi Li Department of Hematology, Xi’an Central Hospital/Xi’an Institute of Hematology
  • Feng Liu Department of Hematology, Xi’an Central Hospital/Xi’an Institute of Hematology
  • Wen Wu Department of Hematology, Xi'an Central Hospital/Xi'an Institute of Hematology
DOI: https://doi.org/10.5937/jomb0-57965
Keywords: acute myeloid leukemia, Prognosis, TNF- a, LIF, IFNγ, IL-2, IL-4, IL-17A

Abstract


Background: To assess the importance of inflammatory factors in predicting outcomes in individuals diagnosed with acute myeloid leukemia.

Methods: Between July 2017 and  December 2019, a total of 100 patients with a recent diagnosis of acute myeloid leukemia (AML) were recruited from the Hematology Department of our hospital’s Cancer Center and assigned to the AML group. Additionally, 60 individuals with no underlying health conditions who underwent standard medical checkups during the same period were selected as the control group. Serum levels of IL-2, IL-4, IL-17A, TNF-α, IFN-γ, and LIF were measured through ELISA. All participants in the AML group were followed up for three years. Based on the European Leukemia Network (ELN) genetic risk stratification criteria, patients were categorized into favorable, intermediate, and adverse prognosis subgroups. Inflammatory marker profiles were then compared among these subgroups.

Results: Compared to healthy individuals, the AML group presented significantly increased serum concentrations of IL-4, IL-17A, and TNF-α, while levels of IL-2, IFN-γ, and LIF were significantly decreased (P < 0.05). Upon stratifying patients by prognostic classification, those in the favorable and intermediate prognosis categories exhibited notably lower IL-4, IL-17A, and TNF-α levels relative to the poor prognosis group (all P < 0.05). In contrast, levels of IL-2, IFN-γ, and LIF were notably elevated in the subgroup with favorable prognostic profiles (all P < 0.05). Additional analysis of cytokine expression indicated that increased levels of IL-4, IL-17A, and TNF-α were linked to worse 3-year survival performance (P < 0.05). Conversely, higher expression of IL-2, IFN-γ, and LIF was significantly associated with better long-term survival outcomes relative to patients with reduced expression levels (P < 0.05).

Conclusion: The abnormal levels of IL-4, IL-17A, TNF-a, IFNγ and LIF in patients with acute myeloid leukemia are increased, while the abnormal levels of IL-2, IFNγ and LIF are decreased, which has certain guiding effect on prognosis assessment and can be used as auxiliary indicators for prognosis assessment of AML.

References

1. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Ne 2021; 19(1): 16-27.
2. Koenig K, Mims A. Relapsed or primary refractory AML: moving past MEC and FLAG-ida. Curr Opin Hematol 2020; 27(2): 108-14.
3. Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review. R I Med J (2013) 2020; 103(3): 38-40.
4. Naji NS, Sathish M, Karantanos T. Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia. Cancers 2024; 16(23): 3974.
5. Lacourt TE, Kavelaars A, Galloway-Pena JR, Sahasrabhojane PV, Shah ND, Futreal A, et al. Associations of inflammation with symptom burden in patients with acute myeloid leukemia. Psychoneuroendocrino 2018; 89: 203-8.
6. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM. Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leukemia Res 2013; 37(3): 274-9.
7. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391-405.
8. Grasselli G, Calfee CS, Camporota L, Poole D, Amato M, Antonelli M, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intens Care Med 2023; 49(7): 727-59.
9. Mambet C, Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, et al. Murine models based on acute myeloid leukemia-initiating stem cells xenografting. World J Stem Cells 2018; 10(6): 57-65.
10. Pollyea DA. New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematol-Am Soc Hemat 2018; 2018(1): 45-50.
11. Dong F, Chen L, Zhao C, Li X, Tan Y, Song H, et al. Predictive values of plasma TNFalpha and IL-8 for intracranial hemorrhage in patients with acute promyelocytic leukemia. Front Med-Prc 2022; 16(6): 909-18.
12. Yuan Y, Tan S, Wang H, Zhu J, Li J, Zhang P, et al. Mesenchymal Stem Cell-Derived Exosomal miRNA-222-3p Increases Th1/Th2 Ratio and Promotes Apoptosis of Acute Myeloid Leukemia Cells. Anal Cell Pathol 2023; 2023: 4024887.
13. Iwaszko M, Bialy S, Bogunia-Kubik K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells-Basel 2021; 10(11):
14. Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer 2021; 9(1):
15. Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Canc Res 2019; 38(1): 6.
16. Wang L, Zhang H, Lei D. microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling. Yonsei Med J 2019; 60(10): 924-34.
Published
2025/06/07
Issue
Vol. 44 No. 8 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Jianghuizi Li, Feng Liu, Wen Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.